USFDA approves Caplin Steriles Acetaminophen Injection for US market

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹1954.00

prior close

₹1914.00

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-2.3%+3.3% vs market

Pharmaceuticals peers, median of 156sector-2.0%+3.0% vs sector

On the reaction day the stock moved 3.3 pts more than Nifty Smallcap 250 and 3.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0-2.3+3.3-2.0+3.0

Next day

-2.7-1.3-1.4-1.3-1.4

-1.3-2.0+0.7-1.4+0.1

+0.0-1.4+1.4-1.0+1.0

+0.2-0.6+0.8-0.8+1.0

+0.1-0.2+0.4-0.6+0.7

-2.8-1.7-1.0-2.1-0.6

15d

-8.0-0.0-8.0-2.0-6.0

-6.9-0.0-6.9-0.8-6.1

-9.8-1.4-8.5-5.0-4.8

-14.6-8.7-5.9-10.8-3.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Caplin Steriles, subsidiary of Caplin Point Laboratories, received final USFDA approval for its generic Acetaminophen Injection in single-dose infusion bags (1000 mg per 100 mL). It is a generic equivalent of Mallinckrodt's product, used for pain and fever management. The US market for this injection had sales of about $86 million for the 12 months ending October 2025. Caplin Steriles now has 43 ANDA approvals out of 53 filed.

Likely market impact

Positive. Opens a new generic product in an about $86 million US market, strengthening Caplin Steriles US portfolio and revenue potential.